1. Metabolic Enzyme/Protease
    Autophagy
  2. Phosphodiesterase (PDE)
    Autophagy

Cilostazol (Synonyms: OPC 13013; OPC 21)

Cat. No.: HY-17464 Purity: 99.34%
Data Sheet SDS Handling Instructions

Cilostazol(OPC 13013; OPC 21) is a potent inhibitor of PDE3A, the isoform of PDE 3 in the cardiovascular system (IC50=0.2 uM).

For research use only. We do not sell to patients.
Cilostazol Chemical Structure

Cilostazol Chemical Structure

CAS No. : 73963-72-1

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $55 In-stock
50 mg $50 In-stock
100 mg $90 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Cilostazol(OPC 13013; OPC 21) is a potent inhibitor of PDE3A, the isoform of PDE 3 in the cardiovascular system (IC50=0.2 uM). IC50 Value: 0.2 uM [1] Target: PDE3A in vitro: Cilostazol caused a concentration-dependent increase in the cAMP level in rabbit and human platelets with similar potency. Furthermore, cilostazol and milrinone were equally effective in inhibiting human platelet aggregation with a median inhibitory concentration (IC50) of 0.9 and 2 microM, respectively. In rabbit ventricular myocytes, however, cilostazol elevated cAMP levels to a significantly lesser extent (p < 0.05 vs. milrinone) [2]. Cilostazol inhibited SIPA dose-dependently in vitro. The IC50 value of cilostazol for inhibition of SIPA was 15 +/- 2.6 microM (m +/- SE, n=5), which was very similar to that (12.5 +/- 2.1 microM) for inhibition of ADP-induced platelet aggregation. Cilostazolpotentiates the inhibition of SIPA by PGE1 and enhances its ability to increase cAMP concentrations [3]. in vivo: A single oral adminstration of 100 mgcilostazol to healthy volunteers produced a significant inhibition of SIPA [3]. Male C57BL/6J mice were assigned to five groups: mice fed a normal diet (groups 1 and 2); 0.1% or 0.3% cilostazol-containing diet (groups 3 and 4, respectively); and 0.125% clopidogrel-containing diet (group 5). Two weeks after feeding, groups 2-5 were intraperitoneally administered carbon tetrachloride (CCl4 ) twice a week for 6 weeks, while group 1 was treated with the vehicle alone [4]. Toxicity: Cilostazol in addition to dual antiplatelet therapy appears to be effective in reducing the risk of restenosis and repeat revascularization after PCI without any significant benefits for mortality or stent thrombosis [5].

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT02374957 Wake Forest University Health Sciences Peripheral Arterial Disease|Claudication (Finding) February 2015 Phase 4
NCT01915069 University of Southern California|Society of Family Planning Contraception July 2013 Phase 2
NCT00446641 Asan Medical Center|Korea Otsuka Pharmaceutical Co., Ltd. Cerebral Infarction March 2007 Phase 4
NCT00822172 Colorado Prevention Center|Otsuka Pharmaceutical Co., Ltd. Peripheral Vascular Disease|Intermittent Claudication|Peripheral Arterial Disease September 2008 Phase 4
NCT00684762 Mutual Pharmaceutical Company, Inc. Therapeutic Equivalency March 2004 Phase 1
NCT00685802 Mutual Pharmaceutical Company, Inc. Therapeutic Equivalency, Healthy June 2004 Phase 1
NCT01841827 Danish Headache Center Migraine April 2013
NCT01378650 Jong Woo Chung|Korea Otsuka Pharmaceutical Co., Ltd.|Asan Medical Center Tinnitus July 2011
NCT01261234 Kobe City General Hospital|Chiba University|Nagoya University|Mie University|Wakayama Medical University|Kyoto University|Osaka University|Kobe University|Foundation for Biomedical Research and Innovation|Okayama University|Yamaguchi University Hospital|Fukuoka University|Nagasaki University In-stent Restenosis After Carotid Artery Stenting December 2010 Phase 4
NCT00130039 Asan Medical Center|Korea Otsuka International Asia Arab Cerebral Infarction|Atherosclerosis August 2005 Phase 4
NCT00886574 Hanyang University|Ajou University School of Medicine|Kyunghee University Medical Center|Korea University Guro Hospital|Inha University Hospital|Inje University|Hallym University Medical Center Type 2 Diabetes Mellitus April 2009 Phase 4
NCT01409564 Seoul National University Hospital|Korea OIAA Alzheimer's Dementia May 2010 Phase 4
NCT01076478 Otsuka Pharmaceutical, Inc., Philippines Polyneuropathy March 2004 Phase 4
NCT02933788 Kangbuk Samsung Hospital|Asan Medical Center Type 2 Diabetes Mellitus October 2016 Phase 4
NCT00938522 Samsung Medical Center Angioplasty, Transluminal, Percutaneous Coronary July 2009 Phase 4
NCT01012193 Gyeongsang National University Hospital Coronary Artery Disease|Percutaneous Coronary Intervention January 2008 Phase 4
NCT00573950 Korea University Anam Hospital Diabetes Mellitus, Type 2|Metabolic Syndrome X December 2007 Phase 4
NCT00272831 Chinese University of Hong Kong Diabetes Mellitus, Type 2|Diabetes Complications December 2005 Phase 4
NCT01142284 Korea Otsuka Pharmaceutical Co., Ltd. Peripheral Artery Disease April 2010 Phase 2
NCT01383395 Samsung Medical Center|Inje University Healthy June 2011 Phase 1
NCT00741286 Inje University|Korea Otsuka Pharmaceutical Co., Ltd. Cerebral Infarction November 2006 Phase 4
NCT00766545 Otsuka Pharmaceutical Co., Ltd. Cerebral Infarction April 1992 Phase 3
NCT00689858 SK Chemicals Co.,Ltd. Healthy May 2007 Phase 1
NCT02770274 Attikon Hospital|University Hospital of Patras Peripheral Arterial Disease December 2016 Phase 3
NCT00839930 Teva Pharmaceuticals USA Healthy February 2004 Phase 1
NCT02983214 University of Ioannina Ischemic Stroke|Peripheral Artery Disease|Diabetes Mellitus, Type 2 November 2016 Phase 4
NCT00776828 Seoul National University Hospital Coronary Artery Disease November 2006 Phase 4
NCT02431013 Ajou University School of Medicine Dyslipidemias|Peripheral Artery Disease April 2015 Phase 1
NCT02486276 Danish Headache Center Migraine June 2015
NCT01482117 Inje University Interaction November 2011
NCT00847860 Peking University First Hospital|Zhejiang Otsuka Pharmaceutical Co., Ltd. Vascular Dementia|Stroke March 2008 Phase 4
NCT02266030 Seoul National University Bundang Hospital Coronary Artery Disease February 2011 Phase 3
NCT01188824 China Medical University Hospital|National Taiwan University Hospital|Shin Kong Wu Ho-Su Memorial Hospital|Tri-Service General Hospital|Far Eastern Memorial Hospital|Changhua Christian Hospital|Chi Mei Medical Hospital|National Cheng-Kung University Hospital|Kaohsiung Medical University Chung-Ho Memorial Hospital|E-DA Hospital|Mackay Memorial Hospital|Cathay General Hospital|En Chu Kong Hospital|Kuang Tien General Hospital|Chung Shan Medical University|Taipei Veterans General Hospital, Taiwan Ischemic Stroke September 2010 Phase 4
NCT02094469 Korea Otsuka Pharmaceutical Co., Ltd. Vasospastic Angina December 2013 Phase 3
NCT02491268 National Cerebral and Cardiovascular Center Mild Cognitive Impairment July 2015 Phase 2
NCT03116269 Ajou University School of Medicine Ischemic Stroke|Endothelial Dysfunction March 1, 2012 Phase 4
NCT03189641 JIMRO Co., Ltd. Coronary Artery Disease May 31, 2017
NCT00234065 Otsuka Pharmaceutical Co., Ltd. Cerebral Infarction December 2003 Phase 4
NCT02098460 Otsuka Beijing Research Institute Severe Hypercholesterolemia October 2013 Phase 4
NCT01952756 National Cheng-Kung University Hospital|Department of Health, Executive Yuan, R.O.C. (Taiwan) Peripheral Arterial Diseases January 2012 Phase 4
NCT02194686 National Cheng-Kung University Hospital|Department of Health, Executive Yuan, R.O.C. (Taiwan) Cardiovascular Diseases January 2013 Phase 4
NCT02174939 National Cheng-Kung University Hospital|Department of Health, Executive Yuan, R.O.C. (Taiwan) Coronary Artery Disease February 2014 Phase 4
NCT00648388 Mylan Pharmaceuticals Healthy March 2004 Phase 1
NCT01870466 Samsung Medical Center Healthy June 2012 Phase 1
NCT00881231 Sandoz Pain January 2004 Phase 1
NCT00272454 Korea Otsuka Pharmaceutical Co., Ltd.|Seoul National University Boramae Hospital|Korea Otsuka International Asia Arab Co., Ltd. Cerebral Infarction January 2006 Phase 4
NCT00333164 Translational Research Informatics Center, Kobe, Hyogo, Japan|Foundation for Biomedical Research and Innovation|Neurology, Tokyo Women's Medical University, School of Medicine|Kobe City General Hospital|Tohoku University|Kyushu University|Department of Neurology, Saiseikai Central Hospital|China National Center for Cardiovascular Diseases Cerebrovascular Disorders May 2006 Phase 3
NCT01995370 Japan Cardiovascular Research Foundation|Otsuka Pharmaceutical Co., Ltd. Noncardioembolic Cerebral Infarction October 2013 Phase 3
NCT00912756 Kansai Rosai Hospital|Association for Establishment of Ebvidence in Interventions Arteriosclerosis Obliterans March 2009 Phase 4
NCT01932203 Inha University Hospital|Otsuka Pharmaceutical Development & Commercialization, Inc. Cerebral Small Vessel Disease July 2013 Phase 4
NCT00620646 Samsung Medical Center Clopidogrel Non-Responsiveness February 2008
NCT00602407 Roxane Laboratories Intermittent Claudication February 2004
NCT00602173 Roxane Laboratories Intermittent Claudication May 2003
NCT00431249 Tungs’ Taichung Metroharbour Hospital Hemodialysis Patients|Peripheral Vascular Disease February 2007 Phase 4
NCT02253004 Herlev Hospital Migraine With Aura|Stroke September 2014 Early Phase 1
NCT01872858 Huashan Hospital Mild Cognitive Impairment November 2010
NCT01291641 Seoul National University Hospital|Korea Otsuka Pharmaceutical Co., Ltd. Hyperlipidemias March 2011 Phase 4
NCT01252056 Otsuka Beijing Research Institute Diabetic Nephropathy March 2010 Phase 4
NCT00838630 Teva Pharmaceuticals USA Healthy November 2003 Phase 1
NCT00891670 Gyeongsang National University Hospital Coronary Artery Stenosis|Maximal Platelet Aggregation|Late Platelet Aggregation|High Post-Treatment Platelet Reactivity May 2009 Phase 3
NCT00915733 Gyeongsang National University Hospital Myocardial Infarction May 2009 Phase 4
NCT01328470 Kyunghee University Medical Center Chronic Kidney Disease|Stable Angina September 2009 Phase 4
NCT00202020 Otsuka Beijing Research Institute|Zhejiang Otsuka Pharmaceutical Co., Ltd. Cerebral Infarction May 2004 Phase 3
NCT01192724 Yonsei University Coronary Artery Disease March 2010 Phase 4
NCT00549978 Korea Otsuka Pharmaceutical Co., Ltd.|Otsuka Pharmaceutical Co., Ltd. Healthy October 2007 Phase 4
NCT02554721 Otsuka Pharmaceutical Co., Ltd. Healthy September 2015 Phase 1
NCT00589927 CardioVascular Research Foundation, Korea|Otsuka Korea Coronary Artery Disease December 2007 Phase 4
NCT02087007 Korea Otsuka Pharmaceutical Co., Ltd. Vasospastic Angina November 2013 Phase 3
NCT01346865 Seung-Jung Park|Otsuka Pharmaceutical Development & Commercialization, Inc.|CardioVascular Research Foundation, Korea Coronary Artery Disease May 2011 Phase 4
NCT00823875 Otsuka Beijing Research Institute Atherosclerosis Cerebral Infarction March 2009 Phase 4
NCT00823849 Otsuka Beijing Research Institute Type 2 Diabetes Mellitus|Arteriosclerosis Obliterans October 2008 Phase 4
NCT00773630 Otsuka Frankfurt Research Institute GmbH Intermittent Claudication December 2008 Phase 1
NCT01031667 Yonsei University|Korea Otsuka Pharmaceutical Co., Ltd. Therapy November 2009 Phase 4
NCT02483169 Asan Medical Center|Korea Otsuka Pharmaceutical Co., Ltd. Brain Ischemia|Intracranial Hemorrhages June 2009 Phase 4
NCT01013532 Asan Medical Center|Korea Otsuka Pharmaceutical Co., Ltd. Brain Ischemia|Intracranial Hemorrhages June 2009 Phase 4
NCT02829151 Yonsei University Critical Limb Ischemia July 2016 Phase 4
NCT02481323 University of Edinburgh|University of Nottingham Cerebral Small Vessel Diseases|Cognitive Impairment|Stroke October 2015 Phase 2
NCT00443287 Sanofi Intermittent Claudication February 2007 Phase 2
NCT00404716 Shenyang Northern Hospital Acute Coronary Syndrome December 2004 Phase 4
NCT01094457 Shenyang Northern Hospital Acute Coronary Syndromes|Percutaneous Coronary Intervention|Clopidogrel Low Responsiveness March 2009 Phase 4
NCT01779401 Chinese Academy of Medical Sciences, Fuwai Hospital|Beijing Municipal Health Bureau|Haemonetics Corporation|Zhejiang Otsuka Pharmaceutical Co., Ltd. Coronary Heart Disease September 2012
NCT00404781 Shenyang Northern Hospital Ischemic Heart Disease|Acute Coronary Syndromes June 2006 Phase 4
NCT01359423 Yonsei University Claudication March 2011
NCT01955200 The First Affiliated Hospital with Nanjing Medical University|National Natural Science Foundation of China Coronary Artery Disease October 2013 Phase 4
NCT02549898 Danish Headache Center Migraine Headache|Migraine Without Aura August 2015
NCT02101411 Taipei City Hospital PRU(Platelet Reactivity Unit)|APT(Antiplatelet Therapy)|HOTPR(High on Treat Platelet Reactivity) January 2015
NCT00132743 Joselyn Cerezo, MD|National Heart, Lung, and Blood Institute (NHLBI)|Rhode Island Hospital Cardiovascular Diseases|Peripheral Vascular Diseases|Atherosclerosis February 2007 Phase 3
NCT00783081 Kowa Research Institute, Inc. Intermittent Claudication November 2008 Phase 2
NCT01895400 Jong Woo Chung|SK Chemicals Co.,Ltd.|Asan Medical Center Recurrent Vestibulopathy July 2013 Phase 3
NCT02374957 Wake Forest University Health Sciences Peripheral Arterial Disease|Claudication (Finding) February 2015 Phase 4
NCT01915069 University of Southern California|Society of Family Planning Contraception July 2013 Phase 2
NCT00446641 Asan Medical Center|Korea Otsuka Pharmaceutical Co., Ltd. Cerebral Infarction March 2007 Phase 4
NCT00822172 Colorado Prevention Center|Otsuka Pharmaceutical Co., Ltd. Peripheral Vascular Disease|Intermittent Claudication|Peripheral Arterial Disease September 2008 Phase 4
NCT00684762 Mutual Pharmaceutical Company, Inc. Therapeutic Equivalency March 2004 Phase 1
NCT00685802 Mutual Pharmaceutical Company, Inc. Therapeutic Equivalency, Healthy June 2004 Phase 1
NCT01841827 Danish Headache Center Migraine April 2013
NCT01378650 Jong Woo Chung|Korea Otsuka Pharmaceutical Co., Ltd.|Asan Medical Center Tinnitus July 2011
NCT01261234 Kobe City General Hospital|Chiba University|Nagoya University|Mie University|Wakayama Medical University|Kyoto University|Osaka University|Kobe University|Foundation for Biomedical Research and Innovation|Okayama University|Yamaguchi University Hospital|Fukuoka University|Nagasaki University In-stent Restenosis After Carotid Artery Stenting December 2010 Phase 4
NCT00130039 Asan Medical Center|Korea Otsuka International Asia Arab Cerebral Infarction|Atherosclerosis August 2005 Phase 4
NCT00886574 Hanyang University|Ajou University School of Medicine|Kyunghee University Medical Center|Korea University Guro Hospital|Inha University Hospital|Inje University|Hallym University Medical Center Type 2 Diabetes Mellitus April 2009 Phase 4
NCT01409564 Seoul National University Hospital|Korea OIAA Alzheimer's Dementia May 2010 Phase 4
NCT01076478 Otsuka Pharmaceutical, Inc., Philippines Polyneuropathy March 2004 Phase 4
NCT02933788 Kangbuk Samsung Hospital|Asan Medical Center Type 2 Diabetes Mellitus October 2016 Phase 4
NCT00938522 Samsung Medical Center Angioplasty, Transluminal, Percutaneous Coronary July 2009 Phase 4
NCT01012193 Gyeongsang National University Hospital Coronary Artery Disease|Percutaneous Coronary Intervention January 2008 Phase 4
NCT00573950 Korea University Anam Hospital Diabetes Mellitus, Type 2|Metabolic Syndrome X December 2007 Phase 4
NCT00272831 Chinese University of Hong Kong Diabetes Mellitus, Type 2|Diabetes Complications December 2005 Phase 4
NCT01142284 Korea Otsuka Pharmaceutical Co., Ltd. Peripheral Artery Disease April 2010 Phase 2
NCT01383395 Samsung Medical Center|Inje University Healthy June 2011 Phase 1
NCT00741286 Inje University|Korea Otsuka Pharmaceutical Co., Ltd. Cerebral Infarction November 2006 Phase 4
NCT00766545 Otsuka Pharmaceutical Co., Ltd. Cerebral Infarction April 1992 Phase 3
NCT00689858 SK Chemicals Co.,Ltd. Healthy May 2007 Phase 1
NCT02770274 Attikon Hospital|University Hospital of Patras Peripheral Arterial Disease December 2016 Phase 3
NCT00839930 Teva Pharmaceuticals USA Healthy February 2004 Phase 1
NCT02983214 University of Ioannina Ischemic Stroke|Peripheral Artery Disease|Diabetes Mellitus, Type 2 November 2016 Phase 4
NCT00776828 Seoul National University Hospital Coronary Artery Disease November 2006 Phase 4
NCT02431013 Ajou University School of Medicine Dyslipidemias|Peripheral Artery Disease April 2015 Phase 1
NCT02486276 Danish Headache Center Migraine June 2015
NCT01482117 Inje University Interaction November 2011
NCT00847860 Peking University First Hospital|Zhejiang Otsuka Pharmaceutical Co., Ltd. Vascular Dementia|Stroke March 2008 Phase 4
NCT02266030 Seoul National University Bundang Hospital Coronary Artery Disease February 2011 Phase 3
NCT01188824 China Medical University Hospital|National Taiwan University Hospital|Shin Kong Wu Ho-Su Memorial Hospital|Tri-Service General Hospital|Far Eastern Memorial Hospital|Changhua Christian Hospital|Chi Mei Medical Hospital|National Cheng-Kung University Hospital|Kaohsiung Medical University Chung-Ho Memorial Hospital|E-DA Hospital|Mackay Memorial Hospital|Cathay General Hospital|En Chu Kong Hospital|Kuang Tien General Hospital|Chung Shan Medical University|Taipei Veterans General Hospital, Taiwan Ischemic Stroke September 2010 Phase 4
NCT02094469 Korea Otsuka Pharmaceutical Co., Ltd. Vasospastic Angina December 2013 Phase 3
NCT02491268 National Cerebral and Cardiovascular Center Mild Cognitive Impairment July 2015 Phase 2
NCT03116269 Ajou University School of Medicine Ischemic Stroke|Endothelial Dysfunction March 1, 2012 Phase 4
NCT03189641 JIMRO Co., Ltd. Coronary Artery Disease May 31, 2017
NCT00234065 Otsuka Pharmaceutical Co., Ltd. Cerebral Infarction December 2003 Phase 4
NCT02098460 Otsuka Beijing Research Institute Severe Hypercholesterolemia October 2013 Phase 4
NCT01952756 National Cheng-Kung University Hospital|Department of Health, Executive Yuan, R.O.C. (Taiwan) Peripheral Arterial Diseases January 2012 Phase 4
NCT02194686 National Cheng-Kung University Hospital|Department of Health, Executive Yuan, R.O.C. (Taiwan) Cardiovascular Diseases January 2013 Phase 4
NCT02174939 National Cheng-Kung University Hospital|Department of Health, Executive Yuan, R.O.C. (Taiwan) Coronary Artery Disease February 2014 Phase 4
NCT00648388 Mylan Pharmaceuticals Healthy March 2004 Phase 1
NCT01870466 Samsung Medical Center Healthy June 2012 Phase 1
NCT00881231 Sandoz Pain January 2004 Phase 1
NCT00272454 Korea Otsuka Pharmaceutical Co., Ltd.|Seoul National University Boramae Hospital|Korea Otsuka International Asia Arab Co., Ltd. Cerebral Infarction January 2006 Phase 4
NCT00333164 Translational Research Informatics Center, Kobe, Hyogo, Japan|Foundation for Biomedical Research and Innovation|Neurology, Tokyo Women's Medical University, School of Medicine|Kobe City General Hospital|Tohoku University|Kyushu University|Department of Neurology, Saiseikai Central Hospital|China National Center for Cardiovascular Diseases Cerebrovascular Disorders May 2006 Phase 3
NCT01995370 Japan Cardiovascular Research Foundation|Otsuka Pharmaceutical Co., Ltd. Noncardioembolic Cerebral Infarction October 2013 Phase 3
NCT00912756 Kansai Rosai Hospital|Association for Establishment of Ebvidence in Interventions Arteriosclerosis Obliterans March 2009 Phase 4
NCT01932203 Inha University Hospital|Otsuka Pharmaceutical Development & Commercialization, Inc. Cerebral Small Vessel Disease July 2013 Phase 4
NCT00620646 Samsung Medical Center Clopidogrel Non-Responsiveness February 2008
NCT00602407 Roxane Laboratories Intermittent Claudication February 2004
NCT00602173 Roxane Laboratories Intermittent Claudication May 2003
NCT00431249 Tungs’ Taichung Metroharbour Hospital Hemodialysis Patients|Peripheral Vascular Disease February 2007 Phase 4
NCT02253004 Herlev Hospital Migraine With Aura|Stroke September 2014 Early Phase 1
NCT01872858 Huashan Hospital Mild Cognitive Impairment November 2010
NCT01291641 Seoul National University Hospital|Korea Otsuka Pharmaceutical Co., Ltd. Hyperlipidemias March 2011 Phase 4
NCT01252056 Otsuka Beijing Research Institute Diabetic Nephropathy March 2010 Phase 4
NCT00838630 Teva Pharmaceuticals USA Healthy November 2003 Phase 1
NCT00891670 Gyeongsang National University Hospital Coronary Artery Stenosis|Maximal Platelet Aggregation|Late Platelet Aggregation|High Post-Treatment Platelet Reactivity May 2009 Phase 3
NCT00915733 Gyeongsang National University Hospital Myocardial Infarction May 2009 Phase 4
NCT01328470 Kyunghee University Medical Center Chronic Kidney Disease|Stable Angina September 2009 Phase 4
NCT00202020 Otsuka Beijing Research Institute|Zhejiang Otsuka Pharmaceutical Co., Ltd. Cerebral Infarction May 2004 Phase 3
NCT01192724 Yonsei University Coronary Artery Disease March 2010 Phase 4
NCT00549978 Korea Otsuka Pharmaceutical Co., Ltd.|Otsuka Pharmaceutical Co., Ltd. Healthy October 2007 Phase 4
NCT02554721 Otsuka Pharmaceutical Co., Ltd. Healthy September 2015 Phase 1
NCT00589927 CardioVascular Research Foundation, Korea|Otsuka Korea Coronary Artery Disease December 2007 Phase 4
NCT02087007 Korea Otsuka Pharmaceutical Co., Ltd. Vasospastic Angina November 2013 Phase 3
NCT01346865 Seung-Jung Park|Otsuka Pharmaceutical Development & Commercialization, Inc.|CardioVascular Research Foundation, Korea Coronary Artery Disease May 2011 Phase 4
NCT00823875 Otsuka Beijing Research Institute Atherosclerosis Cerebral Infarction March 2009 Phase 4
NCT00823849 Otsuka Beijing Research Institute Type 2 Diabetes Mellitus|Arteriosclerosis Obliterans October 2008 Phase 4
NCT00773630 Otsuka Frankfurt Research Institute GmbH Intermittent Claudication December 2008 Phase 1
NCT01031667 Yonsei University|Korea Otsuka Pharmaceutical Co., Ltd. Therapy November 2009 Phase 4
NCT02483169 Asan Medical Center|Korea Otsuka Pharmaceutical Co., Ltd. Brain Ischemia|Intracranial Hemorrhages June 2009 Phase 4
NCT01013532 Asan Medical Center|Korea Otsuka Pharmaceutical Co., Ltd. Brain Ischemia|Intracranial Hemorrhages June 2009 Phase 4
NCT02829151 Yonsei University Critical Limb Ischemia July 2016 Phase 4
NCT02481323 University of Edinburgh|University of Nottingham Cerebral Small Vessel Diseases|Cognitive Impairment|Stroke October 2015 Phase 2
NCT00443287 Sanofi Intermittent Claudication February 2007 Phase 2
NCT00404716 Shenyang Northern Hospital Acute Coronary Syndrome December 2004 Phase 4
NCT01094457 Shenyang Northern Hospital Acute Coronary Syndromes|Percutaneous Coronary Intervention|Clopidogrel Low Responsiveness March 2009 Phase 4
NCT01779401 Chinese Academy of Medical Sciences, Fuwai Hospital|Beijing Municipal Health Bureau|Haemonetics Corporation|Zhejiang Otsuka Pharmaceutical Co., Ltd. Coronary Heart Disease September 2012
NCT00404781 Shenyang Northern Hospital Ischemic Heart Disease|Acute Coronary Syndromes June 2006 Phase 4
NCT01359423 Yonsei University Claudication March 2011
NCT01955200 The First Affiliated Hospital with Nanjing Medical University|National Natural Science Foundation of China Coronary Artery Disease October 2013 Phase 4
NCT02549898 Danish Headache Center Migraine Headache|Migraine Without Aura August 2015
NCT02101411 Taipei City Hospital PRU(Platelet Reactivity Unit)|APT(Antiplatelet Therapy)|HOTPR(High on Treat Platelet Reactivity) January 2015
NCT00132743 Joselyn Cerezo, MD|National Heart, Lung, and Blood Institute (NHLBI)|Rhode Island Hospital Cardiovascular Diseases|Peripheral Vascular Diseases|Atherosclerosis February 2007 Phase 3
NCT00783081 Kowa Research Institute, Inc. Intermittent Claudication November 2008 Phase 2
NCT01895400 Jong Woo Chung|SK Chemicals Co.,Ltd.|Asan Medical Center Recurrent Vestibulopathy July 2013 Phase 3
View MoreCollapse
References
Molecular Weight

369.46

Formula

C₂₀H₂₇N₅O₂

CAS No.

73963-72-1

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

10 mM in DMSO

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Cilostazol
Cat. No.:
HY-17464
Quantity: